Amneal Pharmaceuticals (NYSE:AMRX) Shares Gap Up to $3.84

Amneal Pharmaceuticals Inc (NYSE:AMRX)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $3.57, but opened at $3.84. Amneal Pharmaceuticals shares last traded at $4.04, with a volume of 5,179,103 shares trading hands.

Several equities analysts have recently commented on AMRX shares. ValuEngine raised Amneal Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, November 25th. Svb Leerink cut Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. Guggenheim assumed coverage on Amneal Pharmaceuticals in a research note on Thursday, September 12th. They issued a “sell” rating and a $2.50 price target for the company. Leerink Swann lowered Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. cut Amneal Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Tuesday, November 12th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $9.00.

The company has a quick ratio of 1.50, a current ratio of 2.25 and a debt-to-equity ratio of 6.91. The company’s fifty day moving average price is $3.15 and its 200 day moving average price is $4.30. The company has a market capitalization of $1.12 billion, a P/E ratio of 4.17, a PEG ratio of 3.66 and a beta of 1.52.

Amneal Pharmaceuticals (NYSE:AMRX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.09). The company had revenue of $378.30 million during the quarter, compared to the consensus estimate of $403.90 million. Amneal Pharmaceuticals had a negative net margin of 19.61% and a positive return on equity of 23.17%. The company’s quarterly revenue was down 20.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.28 earnings per share. Research analysts predict that Amneal Pharmaceuticals Inc will post 0.26 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Swiss National Bank lifted its position in shares of Amneal Pharmaceuticals by 2.1% during the 2nd quarter. Swiss National Bank now owns 171,200 shares of the company’s stock valued at $1,228,000 after acquiring an additional 3,600 shares during the period. Atria Investments LLC acquired a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter worth $240,000. Assenagon Asset Management S.A. acquired a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter worth $971,000. Point72 Asset Management L.P. bought a new position in shares of Amneal Pharmaceuticals in the second quarter worth $23,772,000. Finally, Invesco Ltd. increased its position in shares of Amneal Pharmaceuticals by 287.7% in the second quarter. Invesco Ltd. now owns 202,689 shares of the company’s stock worth $1,453,000 after purchasing an additional 150,406 shares during the period. 35.80% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile (NYSE:AMRX)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

See Also: What is a Lock-Up Period?

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.